Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Marked reduction of proteinuria after removal of a growth hormone-producing pituitary adenoma in a patient with focal segmental glomerulosclerosis: a case report and literature review.

CEN case reports·2022

Same author

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.

Hypertension research : official journal of the Japanese Society of Hypertension·2022

Same author

Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma: a multicentric prospective clinical study.

Scientific reports·2022

Same author

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.

Current hypertension reports·2022

Same author

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.

Journal of diabetes investigation·2022

Same author

Electrolyzed hydrogen-rich water for oxidative stress suppression and improvement of insulin resistance: a multicenter prospective double-blind randomized control trial.

Diabetology international·2022

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in

Susumu Ogawa¹, Takefumi Mori, Kazuhiro Nako

¹Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University School of Medicine, 1-1 Seiryo-cho, Aoba-ku, Sendai 980-8574, Japan. ogawa-s@mail.tains.tohoku.ac.jp

Clinical Journal of the American Society of Nephrology : CJASN

|February 1, 2008

Summary

Sarpogrelate reduced albuminuria and inflammatory markers in diabetic nephropathy patients. These beneficial effects on albuminuria and monocyte chemoattractant protein-1 appear distinct from angiotensin II receptor blockers or thiazolidinedione.

Related Experiment Videos

Last Updated: Jul 7, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Area of Science:

Nephrology
Diabetology
Cardiovascular Research

Background:

Diabetic nephropathy is a common complication of diabetes mellitus.
Albuminuria is a key marker of kidney damage in diabetic nephropathy.
Angiotensin II receptor blockers (ARBs) and thiazolidinediones (TZDs) are used to manage diabetic nephropathy.

Purpose of the Study:

To investigate the effects of sarpogrelate on atherosclerotic inflammatory molecules in diabetic nephropathy patients.
To determine if sarpogrelate's mechanism of action differs from ARBs or TZDs.
To examine the relationship between sarpogrelate's effects on inflammatory markers and albuminuria.

Main Methods:

A randomized controlled trial involving 40 diabetic nephropathy patients already on ARBs.
Patients were assigned to receive either sarpogrelate (300 mg/d) or aspirin (100 mg/d) for 16 weeks.
Measurements included plasma adiponectin, plasma and urinary monocyte chemoattractant protein-1 (MCP-1), and urinary albumin-to-creatinine ratio (UACR).

Main Results:

The sarpogrelate group showed increased plasma adiponectin and decreased plasma and urinary MCP-1 and UACR.
A positive correlation was observed between changes in MCP-1 and UACR levels.
No significant differences in MCP-1 or UACR changes were found between sarpogrelate subgroups with or without concomitant TZD treatment.

Conclusions:

Sarpogrelate effectively reduces albuminuria and inflammatory markers (MCP-1) while increasing adiponectin in diabetic nephropathy.
The observed effects of sarpogrelate suggest a mechanism of action distinct from ARBs and TZDs.
Sarpogrelate represents a potential therapeutic option for managing diabetic nephropathy, possibly through novel pathways.